IP Library Granted Patent US 7,125,726
Granted Patent B2
US 7,125,726 · App. 11/144,402 · Granted Oct 24, 2006

Method and kit for diagnosing myocardial infarction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,726
App. No.
11/144,402
Granted
Oct 24, 2006
Kind
B2
Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer.

Claims (7)

1. A method for diagnosing myocardial infarction comprising:

(a) conducting a mass spectrometric analysis on a sample obtained from a patient in a manner effective to maximize elucidation of discernible peptide fragments contained therein; and

(b) comparing mass spectrum profiles of a peptide consisting of SEQ ID NO:1 to mass spectrum profiles of peptides elucidated from said sample; wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide consisting of SEQ ID NO:1 is diagnostic for myocardial infarction.

2. The method of 1 , wherein said sample is an unfractionated body fluid or a tissue sample.

3. The method of 1 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

4. The method of 1 , wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

5. The method of 1 , wherein said patient is a human.

Assignments (2)
GRANT OF SECURITY INTEREST Recorded Jul 25, 2008
From: NANOGEN, INC.
To: PORTSIDE GROWTH & OPPORTUNITY FUND, AS COLLATERAL AGENT
Reel/Frame 021291/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2005
From: JACKOWSKI, GEORGE; THATCHER, BRAD; VREES, TAMMY; YANTHA, JASON; MARSHALL, JOHN
To: ARTEMIS PROTEOMICS LTD
Reel/Frame 016657/0246 →